EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
The primary objective of the trial is to evaluate the clinical anti-tumor activity of EMD
525797 administered as 1-hour intravenous infusion every 3 weeks in terms of progression free
survival (PFS) time in subjects with asymptomatic or mildly symptomatic metastatic
castrate-resistant prostate cancer (mCRPC).